Literature DB >> 15947955

Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997-2001).

Gulay Sain Guven1, Omrum Uzun, Banu Cakir, Murat Akova, Serhat Unal.   

Abstract

In order to identify the characteristics of patients with hematological malignancies (HM) in the presence/suspicion of any accompanying infectious disease, and to find the predictors of mortality in this group, hospital charts of patients with HM consulted by the Infectious Diseases (ID) team for signs/symptoms of any infection between January 1, 1997 and December 31, 2001 were retrospectively reviewed. A total of 1,132 consultations were done for 641 patients: 59.4% of the patients were male and the mean (+/-standard deviation) age of the study participants was 47.9+/-1.4 years. The most common underlying diseases were non-Hodgkin's lymphoma (30.9%), acute myelogenous leukemia (26.2%), and multiple myeloma (10.9%). Clinically and microbiologically documented infections and fever of unknown origin were observed in 43.3%, 38.1%, and 18.5% of the participants, respectively. Bloodstream infections were detected in 134 episodes (20.9%): 56.5% were caused by gram-negative microorganisms. In logistic regression analysis, the presence of pneumonia (OR 7.56, 95% CI 4.84-12.486), invasive fungal infection (OR 4.12, 95% CI 1.78-9.55), relapse or recent diagnosis of the underlying disease (OR 2.82, 95% CI 1.53-5.21) and neutropenia (OR 2.70, 95% CI 1.70-4.31) were identified as statistically significant predictors of mortality.

Entities:  

Mesh:

Year:  2005        PMID: 15947955     DOI: 10.1007/s00520-005-0836-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  13 in total

1.  Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.

Authors:  J Feliu; A Artal; M González Barón; A Berrocal; I Chacón; M L García de Paredes; E Espinosa; A Ordóñez; P Zamora; J M Montero
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes.

Authors:  J A Lecciones; J W Lee; E E Navarro; F G Witebsky; D Marshall; S M Steinberg; P A Pizzo; T J Walsh
Journal:  Clin Infect Dis       Date:  1992-04       Impact factor: 9.079

3.  Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia.

Authors:  S L Gerson; G H Talbot; S Hurwitz; B L Strom; E J Lusk; P A Cassileth
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

4.  A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.

Authors:  P A Pizzo; J W Hathorn; J Hiemenz; M Browne; J Commers; D Cotton; J Gress; D Longo; D Marshall; J McKnight
Journal:  N Engl J Med       Date:  1986-08-28       Impact factor: 91.245

5.  Infections in haematologic neoplasms: autopsy findings.

Authors:  A Nosari; M Barberis; G Landonio; P Magnani; M Majno; P Oreste; P Sozzi
Journal:  Haematologica       Date:  1991 Mar-Apr       Impact factor: 9.941

Review 6.  Bacteremia due to viridans streptococci in neutropenic patients: a review.

Authors:  P Y Bochud; T Calandra; P Francioli
Journal:  Am J Med       Date:  1994-09       Impact factor: 4.965

7.  Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.

Authors:  J P Marie; A Vekhoff; J L Pico; H Guy; A Andremont; H Richet
Journal:  J Antimicrob Chemother       Date:  1998-06       Impact factor: 5.790

8.  Surveillance study of bacteraemic episodes in febrile neutropenic children.

Authors:  H Ariffin; P Navaratnam; H P Lin
Journal:  Int J Clin Pract       Date:  2002-05       Impact factor: 2.503

9.  Fungal infections in cancer patients: an international autopsy survey.

Authors:  G Bodey; B Bueltmann; W Duguid; D Gibbs; H Hanak; M Hotchi; G Mall; P Martino; F Meunier; S Milliken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

10.  Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

Authors:  Thierry Calandra; J Klastersky; H Gaya; M P Glauser; F Meunier; S H Zinner
Journal:  N Engl J Med       Date:  1987-12-31       Impact factor: 91.245

View more
  5 in total

1.  Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia.

Authors:  Cheol-In Kang; Jae-Hoon Song; Doo Ryeon Chung; Kyong Ran Peck; Joon-Sup Yeom; Jun Seong Son; Yu Mi Wi
Journal:  Support Care Cancer       Date:  2011-12-23       Impact factor: 3.603

2.  Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients.

Authors:  Elif Sahin Horasan; Gulden Ersoz; Anil Tombak; Naci Tiftik; Ali Kaya
Journal:  Med Sci Monit       Date:  2011-05

3.  Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration.

Authors:  Benjamin Gershkovich; Shannon M Fernando; Brent Herritt; Lana A Castellucci; Bram Rochwerg; Laveena Munshi; Sangeeta Mehta; Andrew J E Seely; Daniel I McIsaac; Alexandre Tran; Peter M Reardon; Peter Tanuseputro; Kwadwo Kyeremanteng
Journal:  Crit Care       Date:  2019-08-27       Impact factor: 9.097

4.  Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study.

Authors:  Simone Lanini; Aoife C Molloy; Archibald G Prentice; Giuseppe Ippolito; Christopher C Kibbler
Journal:  BMC Infect Dis       Date:  2013-07-12       Impact factor: 3.090

5.  Timeliness of Infectious Diseases Referral and Inappropriate Antibiotic Usage Post-Referral in an Asian Tertiary Hospital.

Authors:  Liang En Wee; Aidan Lyanzhiang Tan; Limin Wijaya; Maciej Piotr Chlebicki; Julian Thumboo; Ban Hock Tan
Journal:  Trop Med Infect Dis       Date:  2019-11-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.